福瑞股份收盘下跌2.48%，滚动市盈率116.75倍，总市值115.82亿元

Company Overview - Furuya Co., Ltd. closed at 43.71 yuan, down 2.48%, with a rolling PE ratio of 116.75 times and a total market value of 11.582 billion yuan [1] - The company ranks 108th in the medical device industry, which has an average PE ratio of 53.65 times and a median of 37.22 times [1] Institutional Holdings - As of the first quarter of 2025, 13 institutions hold shares in Furuya Co., Ltd., all being funds, with a total holding of 6.5628 million shares valued at 213 million yuan [1] Business Focus - Furuya Co., Ltd. specializes in the production and sales of drugs in the liver disease field, development and sales of diagnostic equipment, and related medical services [1] - The company's main product is the Compound Turtle Shell Soft Liver Tablets [1] Financial Performance - In the first quarter of 2025, the company achieved an operating income of 330 million yuan, a year-on-year increase of 2.35% [1] - The net profit was 28.6367 million yuan, reflecting a year-on-year decrease of 32.97% [1] - The sales gross margin stood at 76.76% [1]